Clinical trial · Interventional
TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer
A Phase II Randomized Trial Comparing TNFerade™ Biologic With Capecitabine and Radiation Therapy Followed by Surgical Resection Versus Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine if the addition of TNFerade™ to pre-operative chemoradiotherapy increases the number of pathologic complete responses when compared to pre-operative chemoradiotherapy alone as assessed following complete surgical resection of primary rectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TNFerade™ | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All patients who have biopsy proven T3 or T4 rectal cancer which is confined to the primary tumor site with or without regional lymph node involvement * Patients must be willing to return for follow-up * Patients must be able to give and sign informed consent * Patients must be suitable candidates for surgical resection post-chemoradiation, i.e. no history of severe congestive heart failure or severe pulmonary disease * Life expectancy \> 6 months Exclusion Criteria: * Patients with evidence of distant metastatic disease * Any of the following hematologic abnormalities: hemoglobin (HGB) \< 8.0 gm/dL unable to be corrected with a transfusion; absolute neutrophil count (ANC) \< 1500 cells/mm3; platelets \< 100,000/mm3; activated partial thromboplastin time (APTT) ratio or International Normalized Ratio (INR) \> 1.5 (except in patients who are therapeutically anticoagulated for non-related medical conditions such as atrial fibrillation and whose anti-thrombotic treatment cannot be withheld for vector injection or surgery). * A history of hepatic cirrhosis or present hepatic dysfunction with total bilirubin \> 2.0 mg/dL except for patients with Gilbert's syndrome who must have a direct bilirubin \</= 1.0 mg/dL; AST/ALT \>/= 2.5 times upper limit of normal. * Renal insufficiency as determined by a serum creatinine \> 2.0 mg/dL * Patients may not have received prior therapy with chemotherapy, biologic therapy or radiation therapy for rectal cancer * Significant history of a medical problem that would preclude the patient from undergoing an operative procedure such as a history of severe congestive heart failure or active ischemic heart disease * Concurrent second malignancy requiring systemic therapy * Pregnant or lactating women * Chronic systemic corticosteroid use * Prior surgery for rectal cancer * Patients with history of deep venous thrombosis or pulmonary embolism * Patients with Doppler evidence of deep venous thrombosis at screening * Known history of documented coagulopathy or thrombophilic disorders * Hormone replacement therapy within one month prior to Day 1 * Known history of documented cerebrovascular disease, stroke or transient ischemic attack (TIA) * Surgery within the last one month, excluding diverting colostomy or ileostomy for obstruction
References
Publications (0)
Data not yet available